Younger women respond worse to checkpoint inhibitor therapy

The big dilemma with checkpoint inhibitor therapy is poor response rates in patients who apparently have "cold" tumors (i.e. the anti-tumor immune system is not activated). This article by Castro et al, Nature Communication demonstrates that younger women have tumors with less MHC-based driver mutations.